Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity

The COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA, including cost of manufacture, ease of storage and potentially lower reactogenicit...

Full description

Saved in:
Bibliographic Details
Main Authors: David C. Stirling, Maria de Miguel Ferrer, Sungwon Kim, Madina Wane, Daniel Kysh, Lisa J. Caproni, John S. Tregoning
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2430826
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832593947191410688
author David C. Stirling
Maria de Miguel Ferrer
Sungwon Kim
Madina Wane
Daniel Kysh
Lisa J. Caproni
John S. Tregoning
author_facet David C. Stirling
Maria de Miguel Ferrer
Sungwon Kim
Madina Wane
Daniel Kysh
Lisa J. Caproni
John S. Tregoning
author_sort David C. Stirling
collection DOAJ
description The COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA, including cost of manufacture, ease of storage and potentially lower reactogenicity. However, they have historically underperformed in large animals and human trials due to low immunogenicity. The interplay between antigen expression and the innate immune response impacts the overall immune response to DNA vaccines. Here, we explore the effect of altering non-coding 5’ regions, on the immunogenicity of a closed linear DNA platform, Doggybone™ DNA (dbDNATM), produced by a rapid and scalable cell-free method. Using a mouse model, we found that enhancer sequences and DNA targeting sequences (DTS) increased influenza virus hemagglutinin (HA) expression and improved immune responses. Additional CpG motifs did not provide any immune benefit. We also found that the effect of non-coding sequences was target specific, with differing effects in influenza HA, SARS-CoV-2 Spike and eGFP constructs. To separate the effects of immune sensing of the DNA construct and the expression of the encoded antigen, we combined a separate CpG oligodeoxynucleotide (ODN) with the highest expressing DNA vaccine; we observed reduced expression, but higher inflammation resulting in equivalent immunogenicity. Further refinement is required to fully understand the interplay of factors required for the induction of protective immunity by DNA vaccines.
format Article
id doaj-art-98718cacd30542448f1f5be0fc7f1cad
institution Kabale University
issn 2164-5515
2164-554X
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-98718cacd30542448f1f5be0fc7f1cad2025-01-20T08:15:15ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2024.2430826Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicityDavid C. Stirling0Maria de Miguel Ferrer1Sungwon Kim2Madina Wane3Daniel Kysh4Lisa J. Caproni5John S. Tregoning6Department of Infectious Disease, Imperial College London, London, UKDepartment of Infectious Disease, Imperial College London, London, UKTouchlight Genetics Ltd, Hampton, UKTouchlight Genetics Ltd, Hampton, UKTouchlight Genetics Ltd, Hampton, UKTouchlight Genetics Ltd, Hampton, UKDepartment of Infectious Disease, Imperial College London, London, UKThe COVID-19 pandemic highlighted the need for rapidly deployable, flexible vaccine platforms; particularly RNA which is now being explored for several other pathogens. DNA vaccines have potential advantages over RNA, including cost of manufacture, ease of storage and potentially lower reactogenicity. However, they have historically underperformed in large animals and human trials due to low immunogenicity. The interplay between antigen expression and the innate immune response impacts the overall immune response to DNA vaccines. Here, we explore the effect of altering non-coding 5’ regions, on the immunogenicity of a closed linear DNA platform, Doggybone™ DNA (dbDNATM), produced by a rapid and scalable cell-free method. Using a mouse model, we found that enhancer sequences and DNA targeting sequences (DTS) increased influenza virus hemagglutinin (HA) expression and improved immune responses. Additional CpG motifs did not provide any immune benefit. We also found that the effect of non-coding sequences was target specific, with differing effects in influenza HA, SARS-CoV-2 Spike and eGFP constructs. To separate the effects of immune sensing of the DNA construct and the expression of the encoded antigen, we combined a separate CpG oligodeoxynucleotide (ODN) with the highest expressing DNA vaccine; we observed reduced expression, but higher inflammation resulting in equivalent immunogenicity. Further refinement is required to fully understand the interplay of factors required for the induction of protective immunity by DNA vaccines.https://www.tandfonline.com/doi/10.1080/21645515.2024.2430826VaccineinfluenzainflammationCpGCOVID-19
spellingShingle David C. Stirling
Maria de Miguel Ferrer
Sungwon Kim
Madina Wane
Daniel Kysh
Lisa J. Caproni
John S. Tregoning
Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
Human Vaccines & Immunotherapeutics
Vaccine
influenza
inflammation
CpG
COVID-19
title Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
title_full Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
title_fullStr Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
title_full_unstemmed Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
title_short Modifying non-coding regions of linear DNA vaccines to explore the interplay of expression and inflammation in immunogenicity
title_sort modifying non coding regions of linear dna vaccines to explore the interplay of expression and inflammation in immunogenicity
topic Vaccine
influenza
inflammation
CpG
COVID-19
url https://www.tandfonline.com/doi/10.1080/21645515.2024.2430826
work_keys_str_mv AT davidcstirling modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT mariademiguelferrer modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT sungwonkim modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT madinawane modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT danielkysh modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT lisajcaproni modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity
AT johnstregoning modifyingnoncodingregionsoflineardnavaccinestoexploretheinterplayofexpressionandinflammationinimmunogenicity